Getting Pregnant With Lean PCOS: What the Hormonal Data Actually Shows

Is Getting Pregnant With Lean PCOS Different From Other PCOS?

Lean women with polycystic ovary syndrome show markedly elevated luteinizing hormone (LH) that tracks with the androgen androstenedione, not with any measure of insulin resistance, in a study from Aristotle University of Thessaloniki (Panidis et al. 2005).

Lean PCOS is diagnosed the same way as any other PCOS presentation — using two of three Rotterdam criteria (irregular or absent ovulation, androgen excess, or polycystic ovarian morphology) — in a woman whose BMI sits in the normal range. What differs, according to a growing body of phenotype-specific research, is which upstream signal actually drives the anovulation. Most PCOS fertility content in circulation is built from data collected predominantly in insulin-resistant, higher-BMI cohorts, where excess insulin drives ovarian androgen production and lowers sex hormone-binding globulin (SHBG). That mechanism does not describe lean PCOS well by definition, since fasting insulin in this phenotype is often unremarkable. The Panidis finding points to a separate route entirely: LH hypersecretion feeding androgen production directly, independent of the insulin pathway that dominates the rest of the PCOS fertility literature.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. Everything below about the lean phenotype’s hormonal and treatment-response data carries over unchanged under the new name; this article uses PCOS, since that is still what most readers search.

Most research defines lean PCOS as a BMI under 25, though the cutoff moves lower — usually to 23 — in studies built around Asian populations, since insulin resistance and metabolic risk appear at lower BMI thresholds in that group. That is not a rounding difference: one of the two treatment-response studies further down this page defines “lean” using the lower threshold specifically, which changes who counts as lean depending on which paper is being read and where its participants were recruited.

What Makes Lean PCOS’s Hormonal Profile Distinct?

Anti-Müllerian hormone (AMH) correlated positively with the LH-to-FSH ratio in a 2024 path-analysis study of 110 women with lean PCOS, identifying AMH as a measurable link in the chain driving this phenotype’s anovulation (Pratama et al. 2024).

That Jakarta-based study measured LH, FSH, kisspeptin, neurokinin B, dynorphin, AMH, fasting insulin, HOMA-IR, testosterone, and SHBG in women with lean PCOS specifically — not PCOS broadly, split afterward by BMI — to trace what actually raises the LH:FSH ratio in this phenotype. Two findings stand out. Dynorphin, a neuropeptide involved in the brain’s control of reproductive hormone pulses, was positively associated with the LH:FSH ratio in both a simple correlation and the fuller statistical model, while kisspeptin — often assumed to be the main driver of this axis — showed no direct association with it at all. Separately, a higher HOMA-IR score (a standard insulin-resistance marker) was linked to lower adiponectin and higher leptin, but the paper’s central finding placed AMH, not insulin resistance, directly on the pathway to the elevated LH:FSH ratio that characterizes much of lean PCOS’s reproductive picture.

What Does the Conception-Rate Data Actually Show for Lean PCOS?

None of the named cohorts behind the conception and live-birth rates already published on this site broke their results out by lean phenotype specifically, and that gap is worth stating plainly rather than papering over with a borrowed number.

Those cohorts measured pregnancy and live-birth rates across PCOS as a whole, in populations where the insulin-resistant phenotype is typically overrepresented simply because it is more common in fertility-clinic samples. Applying their pooled percentage to a lean-PCOS reader assumes the same mechanism produced the anovulation in both groups — an assumption the hormonal data above argues against. A woman whose anovulation is driven primarily by LH-linked androgen output, on a normal insulin profile, is not automatically represented by a statistic drawn from a cohort where insulin resistance predicted the outcome.

How Does Lean PCOS Respond to Ovulation Induction and IVF?

In a 226-woman cross-sectional study, the 113 patients with a BMI under 23 needed a lower average total dose of recombinant FSH during IVF stimulation — 2,128 IU versus 2,752 IU in the 113 patients with a BMI over 25 — and had higher AMH concentrations, at 8.80 ng/mL versus 6.85 ng/mL (Muharam et al. 2026).

That Indonesian cohort used a BMI cutoff of 23 to define its lean group — the threshold some guidelines apply specifically to Asian populations — rather than the more common cutoff of 25, which is worth naming, since it means “lean” in this study is a narrower band than in some other phenotype research. Despite the dose and AMH differences, the number of oocytes retrieved, the cleavage rate, and the pregnancy rate were statistically comparable between the two BMI groups. Read plainly: lean PCOS responded to less medication with an equally good outcome on the measures reported, not a better one — a distinction the study’s own framing sometimes blurs.

An older, far smaller study adds a directional signal worth naming for what it does not establish. Comparing just 6 women with lean PCOS against 10 with obese PCOS inside a larger IVF chart review, McCormick et al. 2008 found the lean group retrieved more oocytes per cycle — 22.2 versus 14.3 — on fewer gonadotropin ampules — 18.8 versus 29.2 — with no difference in clinical pregnancy or live-birth rate reported between the two BMI groups. A six-patient arm is not a number to build a conclusion on; it is a number to watch for replication, which is close to what the far larger 2026 Muharam cohort above does, at more than ten times the sample size, in the same direction on medication dose.

The same 2008 chart review also compared lean PCOS against lean women without PCOS undergoing IVF in the same program, and that comparison is arguably the more useful one for a lean-PCOS reader specifically. The PCOS group had more dominant follicles (12.2 versus 7.7), more oocytes retrieved (22.2 versus 12.6), and more embryos frozen (5 versus 1.4) than lean women without the diagnosis. In plain terms: PCOS’s polyfollicular ovarian pattern shows up during stimulation even at a completely normal BMI, and a normal weight does not cancel out the ovarian response that comes with the diagnosis itself — it changes the metabolic picture, not the ovary.

Does a Lower BMI Make Getting Pregnant With PCOS Easier?

Not automatically — anovulation in lean PCOS is exactly as real as anovulation in higher-BMI PCOS, and the 2023 international guideline does not set out a separate treatment pathway for the two (Teede et al. 2023).

The medications used to induce ovulation — letrozole and clomiphene — target the same downstream signal, insufficient FSH release triggering follicle maturation, regardless of which upstream mechanism produced the anovulation. How letrozole works and what its trial-based success rates are is covered in full elsewhere on this site; none of the trials behind those numbers published a lean-specific success rate either, which is the same gap described above showing up again in the treatment literature, not only in the natural-conception literature. What the phenotype data changes is not which drug a clinician reaches for first, but which lab values are worth asking about — a normal fasting insulin does not mean the metabolic work-up is finished, since LH and androstenedione, not insulin, are the values this phenotype’s research keeps returning to. The guideline is explicit that metabolic screening applies to every woman with PCOS regardless of BMI category, not only those above a particular threshold (Teede et al. 2023) — a normal weight is a reason to widen the panel of questions asked, not to narrow it.

Nothing in this section is a substitute for a clinician’s own assessment, and nothing above should be read as a sequence to try independently. Reporting what a specific trial measured — a dose, a hormone level, an oocyte count — is different from recommending that dose or level for any individual reader, and this article is deliberately written as the former.

Who This Research Does Not Help, and What’s Still Unknown

A normal BMI does not rule out insulin resistance in PCOS — a separate study of 201 lean PCOS patients found it real enough to require its own diagnostic cutoff, which means the LH-driven mechanism described above is not the only one operating in every lean-PCOS reader, only the one this article’s fertility-specific research happens to describe.

Lean PCOS is not one hormonal profile either. The four Rotterdam phenotypes — labeled A through D by which two of the three diagnostic features are present — sort differently by BMI, and a lean woman with phenotype A or B (androgen excess plus anovulation) is not describing the same physiology as a lean woman with phenotype D (anovulation and polycystic ovaries without androgen excess). None of the studies cited above stratified their lean cohorts by phenotype letter, which is a second layer of the same absence named earlier in this article — the data that exists describes “lean PCOS” as one group, when the condition itself is not one group.

This also does not answer the timeline question. Nothing above establishes how many cycles, months, or years a lean-PCOS diagnosis typically takes to convert into a pregnancy, by phenotype — that number does not yet exist in the published literature identified for this article. What does exist is a mechanism (LH and AMH, not insulin, drive the anovulation in the studies above) and a treatment-response signal (lean patients may need less medication for a comparable IVF outcome) — real information, but not a personal timeline, and not a substitute for a clinician tracking your own cycles directly.

Common questions